Abstract | BACKGROUND: OBJECTIVE: The efficacy of nasally administered budesonide (400 micrograms/day, administered twice daily) was compared with that of DSCG (31.2 mg/day, administered six times per day) for the treatment of seasonal allergic rhinitis in children. METHODS: A single-blind parallel group study was carried out in 56 children (mean age 12 years) with seasonal allergic rhinitis. Treatment was for 3 weeks, during which patients assessed nasal symptoms, eye symptoms, and overall efficacy. RESULTS: Over the 3-week period, mean scores for the nasal symptoms of blocked nose, itchy nose, and sneezing were significantly lower with budesonide therapy than with DSCG. P values were .021, .0032, and .0016, respectively. Both treatment groups reported reduced scores for runny nose and eye symptoms; no statistically significant difference was observed between budesonide and DSCG. The global efficacy assessment scores show significantly more patients benefited from budesonide therapy than from DSCG treatment. CONCLUSIONS:
|
Authors | W G Fisher |
Journal | Annals of allergy
(Ann Allergy)
Vol. 73
Issue 6
Pg. 515-20
(Dec 1994)
ISSN: 0003-4738 [Print] United States |
PMID | 7998667
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Allergens
- Pregnenediones
- Budesonide
- Cromolyn Sodium
|
Topics |
- Adolescent
- Allergens
(analysis)
- Budesonide
- Child
- Cromolyn Sodium
(adverse effects, therapeutic use)
- Female
- Humans
- Male
- Pollen
(immunology)
- Pregnenediones
(adverse effects, therapeutic use)
- Rhinitis, Allergic, Seasonal
(drug therapy)
|